In many ways, 2023 has been a transformational year where we made significant progress on our Novo Nordisk Pharmatech growth strategy. Our revenue grew significantly to 880 MDKK in net sales and landed 47% higher than 2022 reflecting a good year across all products, and on top of that, we have brought three new products into our pipeline.
![](https://novonordiskpharmatech.com.linux16.scannetserver.dk/wp-content/uploads/2024/06/novo-nordisk-pharmatech-annual-report-2023-1024x577.png)